NXDC Logo
Logo of NXDC

LEXINGTON, Ky., March 5, 2024 (Newswire.com) - NX Development Corp. (NXDC) has achieved another milestone as we proudly announce the recent granting of orphan-drug status by the U.S. Food and Drug Administration (FDA) for Gleolan (aminolevulinic acid HCl). This designation was provided for the “real-time detection and visualization of epithelial ovarian tumors during debulking surgery.”

Dr. Salvatore DeSena, CEO of NX Development Corp., shared this excitement, stating, “On behalf of our entire team, I am proud to announce that NX Development Corp. secured orphan-drug status for Gleolan in ovarian, fallopian tube, and primary peritoneal cancer. This achievement demonstrates NXDC's commitment to exploring new and innovative uses for Gleolan to help patients and surgeons in their fight against these cancers.” 

“This important milestone underlines the capabilities of aminolevulinic acid HCl in fluorescence-guided surgery. As a group, we aim to expand this further, also to other countries as well, providing support to patients and healthcare professionals combating cancer globally,” said Dr. Ulrich Kosciessa, Chairman of the Board of NXDC and CEO of photonamic GmbH & Co KG. (Pinneberg, Germany), parent company to NXDC. 

Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. Gleolan has gained clinical recognition for its use in visualizing malignant glioma tissue during surgery. 

About NX Development Corp.: NX Development Corp., a wholly-owned subsidiary of photonamic GmbH & Co. KG., a member of the SBI Holdings Inc. Group (Tokyo, Japan), is dedicated to revolutionizing cancer care through innovative solutions and groundbreaking developments in fluorescence-guided surgery.

About Gleolan

Zeto secures HITRUST r2 Certification, showcasing its dedication to data protection
HITRUST Risk-Based, 2-year (r2) Certification validates Zeto is committed to strong cybersecurity and protecting sensitive data.

SANTA CLARA, Calif., February 26, 2024 (Newswire.com) - Zeto, Inc., a commercial-stage medical technology company transforming EEG brain monitoring in healthcare with its innovative EEG headset and advanced cloud platform, today announced its ZCP (Zeto Cloud Platform) has earned certified status by HITRUST for information security.

HITRUST Risk-based, 2-year (r2) Certification demonstrates that the organization’s ZCP (Zeto Cloud Platform) has met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. This achievement places Zeto, Inc. in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

"We're proud to affirm our commitment to exceptional data protection and information security standards by securing the distinguished HITRUST r2 Certification," said Aswin Gunasekar, Founder and CEO at Zeto, Inc.

“HITRUST certification is globally recognized as validation that information security and privacy controls are effective and compliant with various regulations. HITRUST certification is considered the gold standard because of the comprehensiveness and applicability of the control requirements, depth of the assurance process, and level of oversight that ensures accuracy,” said Jeremy Huval, Chief Innovation Officer at HITRUST.

About Zeto, Inc.

Zeto, Inc. is an award-winning, privately held medical technology company located in Santa Clara, CA, that is focused on transforming the way electroencephalography (EEG) is performed at hospitals and clinics. Zeto’s revolutionary FDA-cleared EEG headset and cloud platform bring the traditional EEG procedure to the 21st century. The company plans to leverage its hardware and software technology to improve noninvasive monitoring of the brain’s electrical activity and achieve better outcomes for neurological conditions such as epilepsy, sleep disorders, autism, stroke, and concussion.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at [email protected].

SimpliCut Image
SimpliCut single-patient use diamond burs

BREA, Calif., February 26, 2024 (Newswire.com) - Kerr Dental, a leading global manufacturer of quality dental and restorative products, announced the launch of its new SimpliCut™ rotary products today. SimpliCut, a pre-sterilized single-patient use diamond burs line, is designed to maximize efficiencies by eliminating the need for cleaning, sterilization, and processing.

“Multi-use diamond burs require clinicians to pause their workflow to sterilize the tool before it can even be used with the patient,” explains Elizabeth Mascarena, Marketing Manager at Kerr Dental. “Our new SimpliCut line offers clinicians the performance advantages of a multi-use diamond bur line with a conveniently pre-sterilized single-use product that is ready to use, right out of the box.”

Available in packs of 25 pieces, SimpliCut Diamonds are individually wrapped and sterilized to high industry standards for single-patient use. The burs are available in a range of shapes and color-coded grit sizes for easy identification, enabling them to accommodate varied patient needs. SimpliCut’s fast-cutting diamond burs include shanks designed for true concentric running with less wear and tear on the handpiece turbine.

“As for the functionality, the burs are fantastic,” explains Dr. Meredith Newman. “On the enamel, even under the microscope, I did not see any micro-fracturing occurring near the access, which often occurs when using other diamonds or carbide burs. I was able to get through an entire Zirconia crown with only one bur, when in the past (with a different brand) I have required multiples, or specific Zirconia burs that do not work on other materials.”

“SimpliCut is priced competitively, so doctors can have affordable access to the cutting speed, convenience, versatility, and high level of sterilization available in a single, reliable product," says Product Manager Lili Yao.

The new SimpliCut diamond rotary product will be available to order on February 26, 2024. To learn more about SimpliCut, visit go.kerrdental.com/SimpliCut.

Dr. Meredith Newman is a paid consultant of Kerr. The opinions expressed in this article are those of Dr. Newman. Kerr is a medical device manufacture and does not dispense medical advice. Clinicians should use their own professional judgment in treating their patients.

DeepCura UI
DeepCura UI

SAN FRANCISCO, February 26, 2024 (Newswire.com) - DeepCura is at the forefront of healthcare innovation with the launch of its AI Nurse feature, a cutting-edge solution designed to address the critical nursing shortage in the United States. Their AI Nurses offer a personalized and efficient pre-charting routine, gathering essential patient information and facilitating seamless doctor-patient interactions. With the ability to create tailored instructions for each patient, DeepCura's AI Nurses ensure accurate, one-on-one communication, streamlining the healthcare process from pre-visit preparations to post-consultation follow-ups.

This technology not only optimizes the workload on medical professionals but also enhances the patient experience by ensuring their needs are met with precision and care. The AI Nurse is capable of interacting in multiple languages, providing information, and even coordinating telehealth sessions, making healthcare more accessible and inclusive.

As healthcare faces unprecedented challenges, DeepCura's AI Nurse feature represents a significant leap forward in utilizing technology to bridge gaps, improve care quality, and ensure that every patient receives the attention they deserve. Join us in embracing the future of healthcare, where technology and human compassion meet to create a better, more efficient healthcare system for all.

The nursing shortage in the United States has reached a critical point, with healthcare facilities across the nation struggling to meet patient needs due to a lack of qualified nursing staff. This crisis not only compromises patient care but also places immense pressure on existing healthcare workers, leading to burnout and further exacerbating the shortage. Factors contributing to this shortage include an aging population requiring more care, a wave of retirements among the current nursing workforce, and limited capacity in nursing education programs. In this dire context, DeepCura's AI Nurses emerge as a crucial innovation, offering a sustainable and efficient solution to bridge the gap in patient care. By automating routine tasks and facilitating patient engagement, these AI-powered assistants allow healthcare providers to focus more on direct patient care, thereby enhancing the overall efficiency and effectiveness of healthcare delivery in the face of ongoing staffing challenges.

CHICAGO, February 22, 2024 (Newswire.com) - American Society for Transplantation and Cellular Therapy® (ASTCT) presents top awards to leaders in the field of transplantation and cellular therapy at the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®, Feb. 21-24 in San Antonio, Texas. 

Gerard Socie, MD, PhD receives the 2024 ASTCT Lifetime Achievement Award. Dr. Socie's main field of research both clinically and in the lab is focused on Graft-versus-host disease. His research also includes aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), malignant tumors after treatment of aplastic anemia and late effects after allogeneic stem cell transplantation. Dr. Socie is a leader in the field. He was president of the French Society of Hematology (2014-2018) and president of the National University Council in Hematology (2015-2021). As of November 2023, he is the president of the scientific committee of the French National Cancer Institute, a role he will serve in for the next five years. He has been a member of different scientific societies over the years, including ASH (1992), EHA (1993), EBMT (1992), ASTCT (1995). Dr. Socie supervised more than 40 MD and 15 PhD theses and mentored more than 50 foreign fellows. 

The 2024 ASTCT Public Service Award honors the patient advocacy work of Robin Roberts. Robin Roberts is the versatile co-anchor of America’s top-rated morning news program, Good Morning America, with more than 30 years of experience as a producer, reporter and anchor in radio and television. In 2012, Roberts received a life-saving blood stem cell transplant to treat myelodysplastic syndrome (MDS). Over the past 10 years, Roberts has been an advocate for the NMDP Registry. Roberts uses her platform to raise awareness and encourage thousands of people to join the registry. More than 140 of those individuals have gone on to donate life-saving blood stem cells to patients in need.

John F. DiPersio, MD, PhD, receives the honor of delivering the 2024 E. Donnall Thomas Lecture. Dr. DiPersio is a Professor of Medicine and Pathology & Immunology, Director, Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis and the Virginia E. and Sam J. Golman Professor of Medicine. His research focuses on mechanistic and translational aspects of leukemia and stem cell biology. He has played a key role in the clinical development of plerixafor as a mobilizing agent for stem cell transplantation. Dr. DiPersio presents Is Transplantation Only Copacetic? A Personal Tale of Mentors, Trainees and Colleagues, which focuses on examples of progress in the fields of transplantation and cellular therapy, with a focus on not only his own contributions but also acknowledging those who have shaped the field in general.

Additional information about the 2024 award winners is available on the 2024 Tandem Meetings website. 

TridentCare

SPARKS, MD, February 22, 2024 (Newswire.com) - TridentCare is pleased to announce that Mary E. Sweeney has been appointed Senior Vice President (SVP) of Human Resources. Sweeney assumed her role at TridentCare on February 19, 2024.

Sweeney has decades of experience with crucial aspects of human resources, including recruitment and retention, organizational effectiveness, talent management, employment law and compliance, and diversity and inclusion initiatives.  

“I am excited to return back to the health care industry, especially with an organization that is disrupting healthcare by serving patients where they are,”  Sweeney said.

Sweeney last served at Arcadia University where she held the role of Vice President of Human Resources and the Employee Experience.  During her time at Arcadia, Mary made it a priority to enhance the experience of the faculty and staff by rebuilding many of the HR functions. Prior to joining Arcadia in 2020, Mary spent 22 years in the health care industry.  She served most recently as the Senior Vice President of Human Resources and Regional CHRO for the Mid/South Atlantic regions at Trinity Health. There, Sweeney focused on aligning the HR strategy to Trinity’s business strategy. 

According to CEO Dan Buning, “We interviewed numerous qualified candidates and believed Mary had the best overall experience, skills and organizational fit to help lead our TridentCare HR Team. Our people are what allows us to fulfill our mission to provide clinical diagnostic services nationwide across a wide range of home, facility, workplace or institutional settings. We gladly welcome Mary to our Leadership Team.”

About TridentCare 

Based in Sparks, Maryland, TridentCare is the leading provider of portable diagnostic services in the Country, operating in 38 states, servicing a wide variety of patients and clients. Each day, the company deploys experienced medical professionals and leading-edge technology to provide imaging, phlebotomy, laboratory, oxygen, and vascular services to tens of thousands of patients nationwide. For more information about TridentCare, please visit TridentCare.com, and follow us on LinkedIn, Facebook and Instagram.